Anixa Biosciences, Inc. announced that it has added to its Scientific Advisory Board, Jose Conejo-Garcia, MD PhD; Marco Davila, MD PhD; Linda Kelley, PhD; and Daniel Abate-Daga, PhD; the lead scientists from Moffitt Cancer Center developing a novel ovarian cancer CAR-T treatment. Dr. Jose Conejo-Garcia is the Chair of the Department of Immunology and co-leader of the Immunology Program at Moffitt. His research focuses on understanding and targeting mechanisms governing the balance between immunosuppression and protective immunity in the tumor microenvironment, with an emphasis on the role of cancer-driven pathological myelopoiesis. Dr. Marco Davila is a medical oncologist in the Department of Blood and Marrow Transplantation at Moffitt. His clinical focus is utilizing cell therapies to treat patients with hematologic malignancies. Dr. Linda Kelley is a Senior Member and Director of the Cell Therapy facility at Moffitt Cancer Center. Previously she was the head of the Cell Therapy facility at Dana Farber Cancer Institute at Harvard. Dr. Abate-Daga is an Assistant Member of the Department of Immunology at Moffitt. His group is interested in understanding how a new generation of immune receptors (Chimeric Antigen Receptors, conventional T-cell receptors, and others) can be designed to outperform the current products, in both antitumor efficacy and safety.